Collaborative Neuroscience Network, Inc.

Garden Grove, California 92845

0 studies enrolling now · 52 studies all time

What they study most

Adult Attention Deficit Hyperactivity Disorder, Alzheimer Disease, Alzheimer's Disease, Antipsychotic Agents, Binge Eating Disorder, Bipolar Depression, Bipolar I Disorder, Central Nervous System Depressants, Chronic Schizophrenia, Cognitive Dysfunction, Depression, Depressive Disorder, Major

Studies at this site

• A Study of Semorinemab in Patients With Moderate Alzheimer's Disease — Completed
• A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms — Stopped early
• A Trial of the Efficacy and the Safety of RO6889450 (Ralmitaront) vs Placebo in Patients With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder — Completed
• Relative Bioavailability of LY03010 Compared to Listed Drug — Completed
• Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System — Completed
• A Study of Tanezumab in Adults With Chronic Low Back Pain — Completed
• SPD489 Adult Major Depressive Disorder (MDD) Open-label Safety and Tolerability Rollover Extension Study — Stopped early
• SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder — Completed
• Efficacy, Safety, and Tolerability of SPD489 in Adults With Schizophrenia and Predominant Negative Symptoms — Completed
• A Study Of The Efficacy And Safety Of CP-601,927 Augmentation Of Antidepressant Therapy In Major Depression — Stopped early
• Long Term Safety Study of Tanezumab in Chronic Low Back Pain — Stopped early
• A Study to Evaluate the Effects of Basmisanil in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) Treated With Antipsychotics — Completed
• Dasotraline Binge Eating Disorder Extension Study — Completed
• ELND005 in Patients With Mild to Moderate Alzheimer's Disease — Completed
• A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease — Completed
• ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease — Completed
• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Risdiplam (RO7034067) in Healthy Japanese Participants — Completed
• An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia — Completed
• Crossover Bioequivalence Study of Quetiapine Fumarate 300 mg Tablets Under Steady State Fasted Conditions — Completed
• A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment — Completed
• OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females — Completed
• A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins — Completed
• Dasotraline Binge Eating Disorder Study — Completed
• A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD) — Completed
• Staccato Loxapine in Agitated Patients With Bipolar Disorder — Completed
• A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features — Stopped early
• An Outpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Adjunctive Treatment Of Sub-Optimally Controlled Symptoms of Schizophrenia — Stopped early
• Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose — Completed
• Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression — Completed
• A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia — Completed
• Major Depressive Disorder With Mixed Features - Extension — Completed
• PEARL Schizophrenia Maintenance — Completed
• Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder — Completed
• Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy — Completed
• Efficacy and Safety of Flexibly Dosed BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Completed
• A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease — Completed
• Long-term Safety and Tolerability of BMS-820836 in the Treatment of Patients With Treatment Resistant Major Depression — Stopped early
• Safety and Tolerability Study of Aripiprazole IM Depot in Adult Subjects With Schizophrenia — Completed
• Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia — Completed
• Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia — Completed
• A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder — Completed
• Efficacy, Safety, and Tolerability of TC-5619 as Augmentation Therapy to Improve Negative Symptoms and Cognition in Outpatients With Schizophrenia — Completed
• Adult Attention Deficit Hyperactivity Disorder — Completed
• An Open Label Study of Aripiprazole Intramuscular Injection in Subjects With Schizophrenia — Completed
• Efficacy and Safety Study of a Combination Product [Drug:BCI-024 (Buspirone) and Drug:BCI-049 (Melatonin)] to Treat Major Depressive Disorder (MDD) — Completed
• A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia — Completed
• Open Label Extension Assessing the Tolerability of BCI-024 in Combination With BCI-049 in Patients With Major Depressive Disorder (MDD) — Completed
• Aripiprazole Used as Dual Therapy in the Treatement of Patients With Chronic Stable Schizophrenia or Schizoaffective Disorder. — Completed
• Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease — Completed
• Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44 — Completed